Leiters to offer pharmacy fill services for Avanos' ON-Q* Pain Relief System
DENVER, July 16, 2018 /PRNewswire/ -- Leiters, an FDA-registered 503B outsourcing provider of high quality ophthalmology and hospital-based services, and Avanos Medical Inc. (NYSE:AVNS), a medical technology company focused on delivering clinically superior breakthrough medical device solutions to improve patients' quality of life, announced today a preferred provider relationship to fill the ON-Q* Pain Relief System. In the midst of the national drug shortage, many of Avanos' acute and non-acute customers have requested assistance with filling the ON-Q* Pain Relief System. Leiters will serve as a preferred fill service provider for the ON-Q* Pain Relief System.
In light of the opioid epidemic, the ON-Q* Pain Relief System provides a non-opioid alternative for post-operative pain management. ON-Q* is an elastomeric drug delivery system that delivers local anesthetic directly to the surgical site either through a nerve block or a surgeon placed catheter, for post-operative pain relief. It is indicated to significantly reduce use of opioids and to provide better pain relief than opioids alone.
Through this preferred relationship, Leiters offers ON-Q* Pain Relief System customers, primarily hospitals, surgery centers and clinics, a proprietary pharmacy fill service. This service will be provided through two Leiters 503B outsourcing facilities located in San Jose, California and Denver, Colorado. Both facilities are FDA-registered and inspected and follow current Good Manufacturing Practices (cGMP).
"We couldn't be more excited about this new partnership with Avanos. Leiters has been a trusted source of medications for nearly a century. This partnership and the services to be provided illustrate our unwavering commitment to delivering better medicine to more people," said Robin Smith Hoke, Chief Executive Officer of Leiters.
"This new partnership provides our customers with a simple and convenient option for filling the ON-Q* Pain Relief System," said John Tushar, President, Global Franchises, at Avanos Medical. "We are delighted to partner with Leiters. They are dedicated to offering superior pharmacy filling services and we share a mutual commitment to providing quality non-opioid solutions for pain management. At Avanos, we want to be the best at getting patients back to the things that matter; our partnership with Leiters will play an important role in helping us achieve that vision."
About Avanos Medical
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior breakthrough medical device solutions to improve patients' quality of life. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands in more than 90 countries. For more information, visit www.avanos.com.
Forward-Looking Statements – Avanos Medical
This press release contains information that includes or is based on "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the current plans and expectations of management and are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as "may", "believe", "will", "expect", "project", " estimate", "anticipate", "plan", or "continue" and similar expressions, among others. Factors that may cause actual results to differ materially from the anticipated results expressed in such forward looking statements include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the impact of investigative and legal proceedings and compliance risks; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; and changes in the competitive environment. Additional information concerning these and other factors that may impact future results is contained in our filings with the U.S. Securities and Exchange Commission, including Avanos's most recent Form 10-K and Quarterly Reports on Form 10-Q.
Leiters Contact: Kari Cashmore
Avanos Investor Contact: Dave Crawford
Avanos Medical, Inc.
Avanos Media Contact: Raul Damas/Marleen Geerlof